Inhibiting CGRP in migraine prophylaxis



Click here to take our survey

60th Annual Scientific Meeting of the American Headache Society, San Francisco CA, 29 June – 1 July 2018 – Erenumab, the first in a new class of monoclonal antibodies that inhibit calcitonin gene-related peptide (CGRP), has now been approved in the U.S. Other agents in development are fremanezumab, eptinezumab and galcanezumab. The following is a summary of new data on these agents presented at the 60th annual meeting of the American Headache Society.

It takes 30 seconds


What is the most common preventive migraine medication that you currently use?

What is the second-most common preventive migraine medication that you currently use?

When evaluating trial data for CGRP inhibitors, what endpoint do you find most compelling? (pick one)

What endpoint would your migraine patients find most compelling? (pick one)

In your view, what is the minimum duration of follow-up that would provide you with reasonable assurance of the long-term efficacy and safety of CGRP inhibitors?

What do you believe would be the main barrier to initiating prophylaxis with a CGRP inhibitor in your practice?

Recommend to a Colleague

Related Posts

Go back to home page